Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, liver cancer and nasopharyngeal cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy. The clinicopathological data of patients with persistent, recurrent or metastatic cervical cancer treated with Cadonilimab were retrospectively collected, and medical images (magnetic resonance, CT, etc.) before and after treatment were followed up, and the efficacy was evaluated according to RECIST standards. The incidence and severity of adverse events and clinically significant abnormal laboratory test results were collected to evaluate the safety of the drug. Survival benefit analysis is conducted based on the patient's survival time and medical expenses.

Start Date01 Nov 2024

Sponsor / Collaborator

Fujian Cancer Hospital

NCT06371157 / Not yet recruitingPhase 3

A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma

Start Date02 Jul 2024

Sponsor / Collaborator

Akeso Biopharma Co., Ltd.

NCT05856864 / RecruitingPhase 1IIT

An Open, Single-arm, Single-centre,Phase II Clinical Study Evaluating Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

To evaluate the efficacy Cadonilimab in combination with Ramucirumab for the treatment of advanced Hepatocellular Carcinoma that has failed at systemic therapy

Start Date01 Jun 2024

Sponsor / Collaborator

Tianjin Medical University Cancer Institute and Hospital

100 Clinical Results associated with Cadonilimab

100 Translational Medicine associated with Cadonilimab

100 Patents (Medical) associated with Cadonilimab

Literatures (Medical) associated with Cadonilimab

31 Dec 2024·mAbs

A pivotal decade for bispecific antibodies?

Article

Author: Surowka, Marlena ; Klein, Christian

Bispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of mAbs and their adoption as therapeutic agents in the 1980s and 1990s, the development of bsAbs has held substantial appeal. Nevertheless, only three bsAbs (catumaxomab, blinatumomab, emicizumab) were approved through the end of 2020. However, since then, 11 bsAbs received regulatory agency approvals, of which nine (amivantamab, tebentafusp, mosunetuzumab, cadonilimab, teclistamab, glofitamab, epcoritamab, talquetamab, elranatamab) were approved for the treatment of cancer and two (faricimab, ozoralizumab) in non-oncology indications. Notably, of the 13 currently approved bsAbs, two, emicizumab and faricimab, have achieved blockbuster status, showing the promise of this novel class of therapeutics. In the 2020s, the approval of additional bsAbs can be expected in hematological malignancies, solid tumors and non-oncology indications, establishing bsAbs as essential part of the therapeutic armamentarium.

15 Apr 2024·Clinical Cancer Research

Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study

Article

Author: Xia, Yu ; Wang, Li ; Wang, Jing ; Huang, Xin ; Wang, Zhongmin Maxwell ; Liu, Ting ; Li, Guiling ; Cai, Hongbing ; Qin, Wenjing ; Liu, Fei ; Lou, Hanmei ; Liu, Wei ; Li, Baiyong

AbstractPurpose:Immune checkpoint inhibitors (ICI) have been a potential treatment option for patients with cervical cancer in several clinical studies. We investigated the safety and efficacy of cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, plus standard therapy for the first-line treatment of R/M CC (recurrent and/or metastatic cervical cancer).Patients and Methods:Eligible patients were assigned to 3 cohorts: cohort A-15 (cadonilimab 15 mg/kg every 3 weeks (Q3W) plus chemotherapy), cohort A-10 (cadonilimb 10 mg/kg Q3W plus chemotherapy), and cohort B-10 (cadonilimab 10 mg/kg Q3W plus chemotherapy and bevacizumab). They received the corresponding treatments until disease progression, unacceptable toxicity, withdrawal of consent, or investigator decision. The primary objective was safety; the secondary endpoints included objective overall response (ORR), duration of response, disease control rate, progression-free survival, and overall survival. This study is registered with ClinicalTrials.gov (NCT04868708).Results:As of February 13, 2023, treatment-related adverse events (TRAE) occurred in 45 (100.0%) patients. Grade ≥3 TRAEs were reported in 33 (73.3%) patients. Immune-related adverse events (irAE) occurred in 29 (64.4%) patients and grade ≥3 irAEs were observed in 9 (20.0%) patients. Seven (15.6%) of 45 patients permanently discontinued cadonilimab treatment due to TRAEs. One death due to hemorrhagic shock occurred in cohort B-10. Among 44 patients who underwent at least one post-baseline tumor assessment, the ORR was 66.7% in cohort A-15, 68.8% in cohort A-10, 92.3% in cohort B-10, and 79.3% in cohorts A-10 and B-10 combined.Conclusions:Cadonilimab combined with standard therapy was acceptable, with encouraging antitumor activity in patients with R/M CC.

01 Apr 2024·Oral Oncology

Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study

Article

Author: Chen, Qiu-Yan ; Guo, Shan-Shan ; Wu, De-Hua ; Chen, Xiao-Zhong ; Qin, Xin-Tian ; Li, Bai-Yong ; Liu, Wei ; Maxwell Wang, Zhongmin ; Yao, Zhi-Fang ; Mai, Hai-Qiang ; Xu, Rui-Hua ; Chen, Don-Ping ; Jin, Feng ; Lin, Qin ; Qu, Song ; Luo, Ying ; Lin, Shao-Jun ; Tang, Lin-Quan ; Xia, Michelle

OBJECTIVEThis study was designed to assess the efficacy and safety of cadonilimab monotherapy, a first-in-class, bi-specific PD-1/CTLA-4 antibody, in patients with previously treated recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC).PATIENTS AND METHODSThis multicenter, open-label, single-arm, phase II clinical trial enrolled patients with R/M-NPC who had failed first-line platinum-based chemotherapy and second-line single agent or combined chemotherapy, and immunotherapy-naive. Patients received cadonilimab for 6 mg/kg once every 2 weeks (Q2W). The primary endpoint was objective response rate (ORR) in full analysis set (FAS) assessed by investigators according to RECIST v.1.1. The secondary endpoint included progression-free survival (PFS), overall survival (OS), duration of response (DoR), time to response (TTR) and safety.RESULTSA total of 23 patients were assessed. The median time from first dose to data cutoff was 16.56 (range, 0.8-25.2) months. ORR was 26.1 % (95 %CI:10.2-48.4). The ORR were 44.4 % (95 %CI: 13.7-78.8) and 14.3 % (95 %CI:1.8-42.8) in patients with tumor PD-L1 expression ≥50 % and <50 %, respectively. ORR was achieved in 40.0 % (95 %CI:12.2-73.8) of patients with EBV-DNA level <4000 IU/ml (n = 10) and 15.4 % (95 %CI:1.9-45.4) of those with ≥4000 IU/ml. The median PFS was 3.71 months (95 %CI: 1.84-9.30). respectively. Median OS was not reached, and the 12-month OS rate was 79.7 % (95 % CI:54.5-91.9). Only two patients (8.3 %) experienced Grade ≥3 treatment-related adverse events (TRAEs) with hypothyroidism (30.4 %), rash (21.7 %) and pruritus (21.7 %) being the most prevalent TRAEs.CONCLUSIONCadonilimab monotherapy demonstrated a promising efficacy and manageable toxicity in patients with previously treated R-M/NPC and provide an efficacious salvage treatment option.

News (Medical) associated with Cadonilimab

08 Apr 2024

·www.prnewswire.com

Oral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR

SAN DIEGO, April 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb) combined with XELOX (capecitabine plus oxaliplatin) as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (AK104-302/COMPASSION-15) were released presented in the form of oral presentation at the 2024 American Association for Cancer Research (AACR). The COMPASSION-15 is the world's first Phase III clinical study of PD-1/CTLA-4 bispecific antibody combined with chemotherapy as first-line treatment for gastric cancer. In COMPASSION-15 , the proportions of patients with PD-L1 CPS <5 (PD-L1 low expression) and PD-L1 CPS <1 (PD-L1 negative) in the intention-to-treat population (ITT) were 49.8% and 23%, respectively, which is much higher than that in previous Phase III clinical studies of immune checkpoint inhibitors combined regimens for first-line gastric cancer globally. Previous studies have shown that patients with PD-L1 low expression/negative generally have poor efficacy with immunotherapy. As of the interim analysis, with a median follow-up of 18.7 months, the proportions of subsequent systemic treatment in the Cadonilimab combination therapy group and chemotherapy group were 36.4% vs 50.5%, respectively, and the proportions of subsequent treatment using PD-1/PD-L1 inhibitors were 11.1% vs 21.6%, respectively. The results showed that regardless of PD-L1 expression, Cadonilimab combination therapy significantly prolonged patients' overall survival benefits and reduced the risk of death compared to chemotherapy, with outstanding benefits in objective response and long-term survival. Even for the patients with low PD-L1 expression, it also showed excellent efficacy, which is expected to compensate for the limited efficacy of PD-1 monotherapy for first-line treatment of low PD-L1 expression gastric cancer, providing a more comprehensive and efficient immunotherapy regimen for advanced gastric cancer patients. Cadonilimab plus chemo therapy significantly prolonged survival benefits as first-line treatment for advanced gastric cancer, comprehensively reducing the risk of progression/death. l In the ITT population，the median overall survival (mOS) was longer in the combination therapy group versus the chemotherapy group (HR=0.62 ，mOS 15.0mo vs 10.8 mo; P<0.001)，with a 39% prolongation of mOS and a 38% reduction in the risk of death； The OS benefits stratified by different CPS values were consistent with the overall population, with equally excellent efficacy in low PD-L1 expression: When PD-L1 CPS≥5, the mOS of Cadonilimab combination therapy group compared to the chemotherapy group was not reached vs 10.6 months, with a 44% reduction in the risk of death (HR=0.56, P<0.001); When PD-L1 CPS<5, the mOS was 14.8 months vs 11.1 months, with a 33.3% prolongation of mOS and a 30% reduction in the risk of death (HR=0.7, P=0.011); The median progression-free survival (mPFS) in the ITT population was 7.0 months and 5.3 months, respectively, with a 32% prolongation of mPFS and a 47% reduction in the risk of disease progression (HR=0.53, P<0.001). Cadonilimab combination therapy as first-line treatment for advanced gastric cancer is highly efficient in anti-tumor response, doubling the duration of response. The objective response rates (ORR) of Cadonilimab combination therapy and chemotherapy were 65.2% and 48.9%, respectively, with a significant improvement in tumor treatment response with Cadonilimab combination therapy, increasing ORR by 33.3%; The median duration of response (mDOR) with Cadonilimab combination therapy was twice that of chemotherapy (8.8 months vs 4.4 months). Cadonilimab combination therapy significantly enhances long-term survival, with the advantage becoming more prominent with longer follow-up periods. In the ITT population, the 12-month OS rates of Cadonilimab combination therapy vs chemotherapy were 57.3% vs 43.7%; when CPS≥5, the 12-month OS rates were 58% vs 44.1%; when CPS<5, the 12-month OS rates were 56.9% vs 45.1%; In the ITT population, the 18-month OS rates of Cadonilimab combination therapy vs chemotherapy were 45.8% vs 25.5%; when CPS≥5, the 18-month OS rates were 51.2% vs 23.5%; when CPS<5, the 18-month OS rates were 44.1% vs 27.5%; In January 2024, based on the results of the AK104-302/COMPASSION-15 study, Akeso's new drug application (NDA) for Cadonilimab combined with XELOX as first-line treatment for unresectable locally advanced or metastatic G/GEJ adenocarcinoma has been successfully accepted. SOURCE Akeso, Inc.

Clinical ResultPhase 3AACRImmunotherapyNDA

06 Mar 2024

·www.biospace.com

Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC

HONG KONG, March 6, 2024 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparing Cadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with chemotherapy in the first-line treatment for patients with PD-L1 negative (PD-L1 TPS＜1%) non-small cell lung cancer (NSCLC) (NCT05990127). Lung cancer is a prevalent malignancy with significant global incidence and mortality rates. Retrospective studies conducted both worldwide and in China have revealed that PD-L1 negative expression is observed in up to 48% of patients with driver gene-negative NSCLC. Immunotherapy combined with chemotherapy stands as the first-line standard treatment for these patients. However, current treatment approaches provide limited survival benefits for PD-L1 negative patients. Hence, there exists a pressing clinical imperative for novel treatment modalities to enhance patients' clinical outcomes. Compared to PD-1/PD-L1 monoclonal antibodies, PD-1 monoclonal antibody plus CTLA-4 monoclonal antibody combined with chemotherapy provides greater benefits for the PD-L1 negative population. Previous studies have demonstrated that Cadonilimab possesses a "high efficacy, low toxicity" pro shows clinical efficacy in NSCLC patients with PD-L1 negative expression. The previous clinical studies have demonstrated that the combination therapy of cadonilimab as a first-line treatment for advanced gastric cancer and advanced cervical cancer provides significant survival benefits for the all-comer patients, irrespective of their PD-L1 expression levels. Furthermore, it exhibits robust anti-tumor effects even in patients with low PD-L1 expression or negative status. This therapeutic approach effectively addresses the limitations of current PD-1/PD-L1 monoclonal antibody immunotherapy and has the potential to reshape the landscape of cancer treatment. Akeso anticipates that Cadonilimab, in the treatment of PD-L1 negative NSCLC population, will continue its unique advantages observed in gastric and cervical cancers, becoming a new generation of efficient immunotherapy regimen for first-line treatment of advanced PD-L1 negative NSCLC patients. View original content: SOURCE Akeso, Inc. Company Codes: HongKong:9926

ImmunotherapyPhase 3Clinical Result

28 Feb 2024

·www.biospace.com

The promising results of a phase II clinical study for Akeso's Cadonilimab (PD-1/CTLA-4) combined standard treatment for first-line treatment of R/M cervical cancer has been published in Clinical Cancer Research

HONG KONG, Feb. 28, 2024 /PRNewswire/ -- Akeso (9926.HK) announced that the results of a phase II clinical trial for PD-1/CTLA-4 bispecific antibody（cadonilimab）combined with standard treatment (chemotherapy +/- bevacizumab) as first-line treatment for recurrent/metastatic cervical cancer had been published in the official journal of the American Association for Cancer Research (AACR), Clinical Cancer Research, with an impact factor of 11.5. The article comprehensively elaborates on the excellent therapeutic effects of cadonilimab as first-line treatment for the whole population of cervical cancer, demonstrating the good safety pro this treatment regimen. The publication of this article further enriches the evidence-based medicine evidence for the clinical application of cadonilimab. The study data published in Clinical Cancer Research this time continues to demonstrate the pronounced advantages presented in the data published at the 2022 American Society of Clinical Oncology (ASCO) annual meeting, and with further extension of follow-up time, the efficacy advantage of cadonilimab combined with standard treatment for first-line treatment of recurrent/metastatic cervical cancer becomes more evident. Once again, it shows the clinical potential of cadonilimab for the entire population of recurrent/metastatic cervical cancer regardless of PD-L1 expression status, with the main research data superior to the data disclosed in current standard of care with immunotherapy-based combination therapy (non-head-to-head). Compared to the data disclosed at ASCO in 2022, the overall objective response rate (ORR) remains at a high level, with the disease control rate (DCR) increasing to 100%, and the complete response (CR) rate further increasing. 63.6% of patients experienced tumor reduction of more than 50%. The ORR of the 10mg/kg Q3W dose group (cadonilimab 10mg/kg Q3W + chemotherapy +/- bevacizumab) reached 79.3%, and when combined with bevacizumab, the ORR was as high as 92.3%. The population with PD-L1 CPS <1 accounted for 41.4%, and the ORR of this population was 75.0%, indicating that cadonilimab combined with standard treatment could provide clinical benefit for PD-L1-negative patients. Cadonilimab combined standard treatment brings excellent long-term survival benefits. The median follow-up time for the cadonilimab 15mg/kg Q3W + chemotherapy group was 20.24 months, the median progression-free survival (mPFS) was 11.10 months, the median overall survival (mOS) was not reached, and the 12-month OS rate was 93.3%. The median follow-up time for the cadonilimab 10mg/kg Q3W + chemotherapy group was 18.3 months, the mPFS was 7.06 months, the mOS was not reached, and the 12-month OS rate was 87.5%. The median follow-up time for the Cadonilimab 10mg/kg Q3W + chemotherapy + bevacizumab group was 15.01 months, and neither mPFS nor mOS was reached. The safety of cadonilimab combined with standard treatment is manageable, and no new safety signals have been observed. Reports indicate that in 2020, there were approximately 604,000 new cases of cervical cancer globally, with over 110,000 cases in China. It is estimated that by 2040, the number of deaths from cervical cancer in China will reach 75,000 cases, representing a 26.3% increase compared to 2020. The 5-year survival rate for advanced cervical cancer is only about 17.0%. In first-line treatment for advanced cervical cancer, chemotherapy+/-bevacizumab is the standard treatment regimen domestically, with limited efficacy and no approved immune combination therapy. Cadonilimab was approved by the China National Medical Products Administration (NMPA) in June 2022 for second-line treatment of recurrent/metastatic cervical cancer. Since its launch, Cadonilimab's outstanding clinical value and good safety pro been strongly validated in numerous clinical studies and real-world clinical applications. It has demonstrated prominent benefits for the entire population of patients with advanced cervical cancer, improving survival rates and quality of life, thus addressing the current important clinical need. In November 2023, an interim analysis of a randomized, double-blind, placebo-controlled phase III study of cadonilimab as first-line treatment for cervical cancer showed that the primary endpoint of progression-free survival (PFS) had been met. Soon, the population of patients with advanced cervical cancer in China will have access to immune combination therapy. Additionally, a randomized, double-blind, placebo-controlled Phase III study of cadonilimab combined with chemotherapy as first-line treatment for gastric cancer also met the primary endpoint of overall survival (OS) in the interim analysis, and a new drug application had been accepted by CDE. With positive results from registration trials of cadonilimab in first-line treatments of multiple tumor types, the population benefiting from cadonilimab will rapidly expand, better realizing the clinical value of this cadonilimab for tumor treatment and benefiting more patients. About Cadonilimab Cadonilimab is a first-in-class bispecific antibody targeting both PD-1 and CTLA-4 which is developed by Akeso. In Jun 2022, the China National Medical Products Administration (NMPA) approved cadonilimab for recurrent or metastatic cervical cancer. Cadonilimab has been included and recommended in multiple clinical practice guidelines such as CSCO. Cadonilimab has been engaged in more than 60 ongoing clinical trials including investigator-initiated studies. Currently, a phase III study of cadonilimab for first-line treatment of gastric cancer has met its endpoint of OS. A phase III study of cadonilimab has also met one of its primary endpoints of PFS for first-line treatment of recurrent/metastatic cervical cancer (R/M CC). About Akeso, Inc. Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address significant medical needs globally. Since our inception , we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode. Akeso is actively developing a diverse pipeline of over 30 innovative assets in areas such as cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, NDAs for 4 drugs and 6 indications accepted, and 13 ongoing Phase III studies. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug to the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies. In June 2022, cadonilimab was approved by the NMPA and became the first commercialized bispecific IO drug globally. Another Akeso internally discovered and developed oncology product, penpulimab (a PD-1 antibody), was granted marketing approval in China in August 2021. In December 2022, Akeso entered into a collaboration and license agreement for up to US$5 billion with Summit Therapeutics to accelerate global development and commercialization of ivonescimab. In August, the NDA submission of ivonescimab was accepted by China's NMPA and granted Priority Review. Akeso is listed on the Main Board of the Stock Exchange of Hong Kong Limited. Contact Akeso Public Relations: PR@akesobio.com Contact Akeso Business Development : bd@akesobio.com View original content: SOURCE Akeso, Inc. Company Codes: HongKong:09926, OTC-PINK:LNVGY, HongKong:9926

Clinical ResultPhase 3Phase 2License out/inDrug Approval

100 Deals associated with Cadonilimab

External Link

KEGG	Wiki	ATC	Drug Bank
D12190	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Uterine Cervical Cancer	CN	Akeso Pharmaceuticals, Inc.	28 Jun 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Gastroesophageal Junction Adenocarcinoma	Phase 3	-	Akeso Biopharma Co., Ltd.	01 May 2024
Locally Advanced Cervical Carcinoma	Phase 3	CN	Akeso Biopharma Co., Ltd.	08 Jun 2022
Locally Advanced Gastroesophageal Junction Adenocarcinoma	Phase 3	CN	Akeso Biopharma Co., Ltd.	17 Sep 2021
Metastatic Carcinoma to the Uterine Cervix	Phase 3	CN	Akeso Biopharma Co., Ltd.	27 Aug 2021
Melanoma	Phase 2	CN	Akeso Biopharma Co., Ltd.	20 Dec 2019
Advanced Gastric Adenocarcinoma	Phase 2	CN	Akeso Biopharma Co., Ltd.	18 Jan 2019
Advanced Malignant Solid Neoplasm	Phase 2	CN	Akeso Biopharma Co., Ltd.	18 Jan 2019
Esophageal Squamous Cell Carcinoma	Phase 2	CN	Akeso Biopharma Co., Ltd.	-
Esophageal Carcinoma	Phase 1	CN	Akeso Pharmaceuticals CJSC	18 Jan 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05008783 (COMPASSION-15, AACR2024) Manual	Phase 3	Advanced gastric carcinoma First line	610	Cadonilimab + chemo	(zqvfgvcvbx) = zrlargpycq ruyxrtosjz (fvknhgdamm, 12.3-19.3) View more	Positive	07 Apr 2024
				Cadonilimab + chemo (PD-L1 CPS≥5)	(zqvfgvcvbx) = kxnlhampjb ruyxrtosjz (fvknhgdamm, 11.4-NE) View more
ESMO_ASIA2023 Manual	Not Applicable	Gastrooesophageal junction cancer \| Stomach Cancer First line PD-L1 CPS≤5	22	Cadonilimab+chemotherapy	(zyatfqzngq) = gqiwjourpt qhtwzfkegl (gryneqwkuw ) View more	Positive	02 Dec 2023
NCT05319431 (ASCO_GI2024) Manual	Phase 2	Unresectable Hepatocellular Carcinoma	60	Cadonilimab 10mg/kg + Lenvatinib	(sjloswsrjo) = zvmdlqedks skayfzfntc (depojuuduc, 60.8 ~ 87.3) View more	Positive	18 Jan 2024
NCT04444167 (ESMO2023) Manual	Phase 1/2	Advanced Hepatocellular Carcinoma First line	59	Cadonilimab + lenvatinib	(hxoondcgbx) = qjbddhpjtp rrukxubzua (jxzpspgfhn, 23.6 - 49.1) View more	Positive	23 Oct 2023
				Cadonilimab + lenvatinib	(hxoondcgbx) = xjagtccoan rrukxubzua (jxzpspgfhn, 18.6 - 55.9) View more
NCT03852251 (COMPASSION-03, Pubmed) Manual	Phase 1/2	Solid tumor	240	cadonilimab	(urjbqnepvr) = xygkxrqthz bzjdtwnjyp (suipirsadp ) View more	Positive	01 Oct 2023
				cadonilimab (cervical cancer)	(epkikbsqdy) = oqxboycbqs pcdoestpoj (ecbeanmkuk, 23.3 - 42.5)
NCT05008783 (AK104-302, PRNewswire) Manual	Phase 3	Gastroesophageal junction adenocarcinoma First line	-	Cadonilimab+capecitabine+oxaliplatin	(fqmybeerty) = The trial achieved its primary endpoint by demonstrating a statistically significant overall survival (OS) improvement. spcmroksep (upzgtixbfh ) Met	Superior	07 Nov 2023
				Placebo+capecitabine+oxaliplatin
NCT04982237 (AK104-303, NEWS) Manual	Phase 3	Uterine Cervical Cancer First line	-	卡度尼利+化疗±贝伐珠单抗	- Met View more	Positive	23 Nov 2023
				安慰剂+化疗±贝伐珠单抗
NCT04868708 (COMPASSION-13, Literature) Manual	Phase 2	Uterine Cervical Cancer First line	45	cadonilimab 15mg/kg Q3W+chemotherapy	(hcyfityesf) = mwtuywfvvx ztrfxhkjkz (lwszzqfzqh )	Positive	19 Feb 2024
				cadonilimab 10mg/kg Q3W+chemotherapy	(hcyfityesf) = ehnccyzzig ztrfxhkjkz (lwszzqfzqh )
NCT03261011 (COMPASSION-01, Literature) Manual	Phase 1	Advanced Malignant Solid Neoplasm	119	Cadonilimab	(nmjtyldjco) = bnobqgcrep spzzlkpage (fbksqxxout ) View more	Positive	17 Oct 2023
ChiCTR2200067161 (ESMO_ASIA2023) Manual	Phase 2	Hepatocellular Carcinoma Neoadjuvant	18	cadonilimab	-	Positive	02 Dec 2023
				cadonilimab+FOLFOX-HAIC	(imzaravcfz) = qkcddnrlto wlayrdhbbg (tndqnczoed ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis